Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Myositis Mysteries

Kathleen M. Coyle, MD, Paul H. Plotz, MD, and Mark F. Gourley, MD  |  Issue: January 2008  |  

Dr. Coyle is a clinical fellow in rheumatology at the National Institute of Arthritis, Skin and Musculoskeletal Diseases (NIAMS), National Institutes of Health (NIH) in Bethesda, Md. Dr. Plotz is chief of the arthritis and rheumatism branch of NIAMS/NIH. Dr. Gourley is program director of rheumatology fellowship training at NIAMS/NIH. This article was supported by the Intramural Research Program of NIAMS/NIH.

References

  1. Di Martino SJ, Kagen LJ. Newer therapeutic approaches: Inflammatory muscle disorders. Rheum Dis Clin North Am. 2006;32:121-128, ix.
  2. Bohan A, Peter J. Polymyositis and dermatomyositis (first of two parts). New Engl J Med. 1975;(292):344-347.
  3. Bohan A, Peter J. Polymyositis and dermatomyositis (second of two parts). New Engl J of Med. 1975;(292):403-407.
  4. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol. 2006;253 [Suppl 5], V/2-V/8.
  5. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol. 2004;18(3):331-344.
  6. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855-1859.
  7. Levine SM. Cancer and myositis: New insights into an old association. Curr Opin Rheumatol. 2006;18(6):620-624.
  8. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613.
  9. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005-1012.
  10. Ideura G, Hanaoka M, Koizumi T, et al. Interstitial lung disease associated with amyopathic dermatomyositis: Review of 18 cases. Respir Med. 2007;101(7):1406-1411.
  11. Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin. 2005;23(2):397-428.
  12. Wortmann RL. Inflammatory Diseases of Muscle and Other Myopathies. In: Harris ED, Ruddy S, Budd RC, et al., eds. Kelly’s Textbook of Rheumatology, Seventh Edition. 2, 1309-1335. 2005. Philadelphia PA, Elsevier Saunders.
  13. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):859-890, viii.
  14. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998; 41(3):392-399.
  15. Dalakas MC, Illa A, Dambrosia JM, et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. New Engl J Med. 1993;329:1993-2000.
  16. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med. 1991;91(2):162-168.
  17. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;22;353(9166):1762-1763.
  18. Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006;8(3):167-173.
  19. Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J. 2006;82(969):417-424.
  20. Griggs RC. The current status of treatment for inclusion-body myositis. Neurology. 2006;24;66(2 Suppl 1):S30-S32.
  21. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326.
  22. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40:1262-1273.
  23. IMACS Web site. https://dir-apps.niehs.nih.gov/imacs/index.cfm?action=home.main. Last accessed December 4, 2007.

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Tashatuvango / shutterstock.com

    Myositis-Specific Antibodies Identified

    The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

    Inflammatory Myopathies Difficult to Diagnose, Treat

    Without a single set of diagnostic criteria for identifying polymyositis, dermatomyositis, or myositis and scant evidence-based therapeutic guidelines, these rare muscle diseases can be hard to manage